US stock futures climb suggesting a positive open for Wall Street on the first day of the month. Healthcare and biotechnology stocks have helped to spur new bullish sentiment heading into the summer months and even though the markets closed weaker during the final days of May, June may be seeing a rebound. More volatile stocks like those in biotech have taken on a bigger focus in the markets in 2015 and it’s not just he bigger stocks seeing this either. Penny stocks, which are inherently volatile, have also seen activity bolstered even during these early summer months.
Historically summer months have meant the “slow season” for active traders in the stock market. Vacations, family outings, and simply taking time off have all been reasons for attention to be focused on anything but the stock market. This year however may be a bit different as the outlook on consumer spending suggests that money is being socked away versus being used for consumer goods. U.S. consumer spending growth mysteriously put the breaks on in April when households simply cut back on purchases of things like automobiles and opted instead to build savings. This has suggested that the economy was struggling to gain momentum early in the second quarter. So with “spare change” lying around, are investors using it to put that back into the market? This week companies like Enviro-Serv, Inc. (OTCMKTS:EVSV), Oncothyreon, Inc. (NASDAQ:ONTY), Clean Diesel Technologies, Inc. (NASDAQ:CDTI), Amarin Corp. Plc (NASDAQ:AMRN), Accurexa Inc. (OTCMKTS:ACXA), and US Precious Metals Inc. (OTCMKTS:USPR) have all begun to see surges in price, volume or both even as the summer months have begun to roll in.
This morning Enviro-Serv announced the Company’s largest contract to date. It marked a milestone for Enviro-Serv, and moreover this particular agreement also acts as a beta test in proving [Enviro-Serv’s] concept and securing future business from their new client. Noah Bressack, Florida Realtor and property manager for RE/MAX Bay to Bay stated, “As I approach 60 managed properties under my control it’s imperative I find lower cost more convenient methods of termite eradication to appease both my clients the property owner’s and of course our tenants most importantly. Chris Trina and X-Terminate Pest Management seem to be a perfect fit going forward, and if this first contract goes well this week I will have a lot more work for this company going forward.”
Tuesday morning the share price for Enviro-Serv has jumped from a close on Monday of $0.001 to hitting a high of $0.0013 before 11AM, up another 30%.
Over the last 3 and a half weeks, shares of Oncothyreon have seen an increase in price from initial levels around $1.40 to highs this week of $4.69. It would appear that these positive trial results have been a boon to shareprice appreciation heading into the early weeks of June. Oncothyreon announced that it had presented positive data from its trials of ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor for the treatment of breast cancer, at the American Society of Clinical Oncology 2015 Annual Meeting. “Oncothyreon is currently planning a blinded, randomized placebo-controlled Phase 2 trial of ONT-380 in combination with Herceptin and Xeloda for the treatment of HER2-positive metastatic breast cancer in patients who have failed both Perjeta(R) (pertuzumab) and Kadcyla, which we expect to initiate late this year,” said Diana Hausman, M.D., Chief Medical Officer of Oncothyreon. “The trial design includes endpoints focused on the prevention and treatment of CNS metastases. We have also now enrolled over 40 patients in our trial of ONT-380 in combination with Kadcyla and continue to evaluate this combination for the treatment of patients with CNS metastases.”
Tuesday morning shares of Clean Diesel jumped 65% from its Monday closing price of $2.05. Volume has also trending well above average during the early Tuesday morning session. The Company, which utilizes a proprietary patented “Mixed Phase Catalyst” technology along with other related technologies, provides high-value sustainable solutions to reduce emissions, increase energy efficiency and lower the carbon intensity of on- and off-road combustion engine systems. Tuesday morning the Company announced initial vehicle test results for Spinel(TM). This is the Company’s proprietary clean emissions exhaust technology and is expected to dramatically reduce the cost for auto manufacturers to attain increasingly stringent clean air standards. According to Clean Diesel, the data gathered, demonstrated that a Spinel underfloor catalyst with 97% less platinum group metal (PGM) “achieved emissions control performance equivalent to the OEM catalyst.”
Last week Amarin Corp. Plc announced that its President and Chief Executive Officer, John F. Thero, is scheduled to present a general company update at the Jefferies 2015 Global Healthcare Conference. Though some are speculating on short interest in Amarin, price movement has suggested the opposite to that over the last 3 days. Since last Thursday, shares of AMRN have jumped by as much as 45% following highs of $2.80. Amarin focuses more on cardiovascular health. Currently the company’s first product Vascepa(R) (icosapent ethyl) capsules, is a highly pure EPA omega-3 prescription product.
Accurexa, Inc., is a biotech company focused on developing two programs in its current pipeline, which include Accurexa’s BranchPoint device designed to deliver stem cells or gene therapy as well as its ACX-31, which works to deliver temozolomide, a chemotherapy drug, directly to brain cancer sites with it BranchPoint device. Over the last 2 weeks, this relatively dormant stock has begun to seen an increase in trading momentum and price. Since the last week of May, price has moved from lows of $0.60 to highs on Tuesday of $0.70 and volume, though relatively lighter in comparison to the previous companies mentioned, has begun to see an increase as well. According to Accurexa, its BranchPoint device was developed at the University of California, San Francisco with $1.8 million in funding from the California Institute for Regenerative Medicine and is based on a neurosurgical delivery platform, which was exclusively licensed from UCSF.
Earlier this year, U.S. Precious Metals announced the hiring of ACT HOLDINGS, LLC, to be the operator for the Company’s 2015 core drilling program on its mining concessions located in Michoacan, Mexico. According to the Company, the program initially consists of 5,000 meters that target areas near drill holes from prior drilling campaigns to expand and define known mineralized zones at depth. As of the most recently filed quarterly, US Precious metals has realized an increase in cash and assets by more than $298,000USD. Over the course of the last month (since May 1st) shares of USPR have increased in price by as much as 74% from lows of $0.111 to highs last Friday of (5-29-15) of $0.1999.